{"id":477020,"date":"2020-03-31T17:12:02","date_gmt":"2020-03-31T17:12:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477020"},"modified":"2020-03-31T17:12:02","modified_gmt":"2020-03-31T17:12:02","slug":"alzheimers-disease-clinical-trial-insight-pipeline-assessment-emerging-drugs-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/alzheimers-disease-clinical-trial-insight-pipeline-assessment-emerging-drugs-delveinsight_477020.html","title":{"rendered":"Alzheimer&#8217;s Disease Clinical Trial Insight, Pipeline Assessment, Emerging Drugs | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585632784.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Alzheimer\\'s Disease Clinical Trial Insight, Pipeline Assessment, Emerging Drugs | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585632784.jpeg\" alt=\"Alzheimer\\'s Disease Clinical Trial Insight, Pipeline Assessment, Emerging Drugs | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Alzheimer&#8217;s disease (AD) Pipeline Insight, 2020<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-pipeline-insight\" target=\"_blank\">DelveInsight has launched a new report on Alzheimer&#8217;s disease (AD) Pipeline Insight, 2020<\/a><\/p>\n<p style=\"text-align: justify;\">&#8220;<strong>Alzheimer&#8217;s disease (AD) Pipeline Insight, 2020<\/strong>&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;<strong>Alzheimer&#8217;s disease (AD)&nbsp;<\/strong>market. A detailed picture of the&nbsp;<strong>Alzheimer&#8217;s disease (AD)&nbsp;<\/strong>pipeline landscape is provided, which includes the disease overview and&nbsp;<strong>Alzheimer&#8217;s disease (AD)&nbsp;<\/strong>treatment guidelines. The assessment part of the report embraces in-depth&nbsp;<strong>Alzheimer&#8217;s disease (AD)&nbsp;<\/strong>commercial assessment and clinical assessment of the&nbsp;<strong>Alzheimer&#8217;s disease (AD)&nbsp;<\/strong>pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;<strong>Alzheimer&#8217;s disease (AD)&nbsp;<\/strong>collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies working on Alzheimer&#8217;s disease are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Neurotrope bioscience<\/li>\n<li>AgeneBio<\/li>\n<li>Amarantus Bioscience<\/li>\n<li>Alkahest<\/li>\n<li>vTv Therapeutics<\/li>\n<li>Axsome Therapeutics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And Many Others.<\/p>\n<p style=\"text-align: justify;\">The launch of the emerging therapies is expected to significantly impact the Alzheimer&#8217;s disease treatment scenario in the upcoming years:-<\/p>\n<p style=\"text-align: justify;\">&nbsp;<strong>Drugs Covered:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Bryostatin-1<\/li>\n<li>AGB101<\/li>\n<li>Eltoprazine<\/li>\n<li>AKST\/GR F6019<\/li>\n<li>Azeliragon (TTP488)<\/li>\n<li>AXS-05<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">And Many Others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a Free Sample Report @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alzheimers-disease-ad-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/alzheimers-disease-ad-pipeline-insight<\/a><\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/eef466369c955247f8785dd470da0625.png\" alt=\"\" \/>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Alzheimer&#8217;s disease (AD)&nbsp;Analytical Perspective by DelveInsight<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>In-depth Alzheimer&#8217;s disease (AD) Commercial Assessment of products&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing\/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Alzheimer&#8217;s disease (AD) Clinical Assessment of products&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The&nbsp;Alzheimer&#8217;s disease (AD)&nbsp;report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em>Alzheimer&#8217;s disease (AD)&nbsp;across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li>It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em>Alzheimer&#8217;s disease (AD)&nbsp;<em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li>Detailed&nbsp;Alzheimer&#8217;s disease (AD)&nbsp;<em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;Alzheimer&#8217;s disease (AD).<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Report highlights<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>A better understanding of disease pathogenesis contributing to the development of novel therapeutics for&nbsp;Alzheimer&#8217;s disease (AD).&nbsp;&nbsp;&nbsp;&nbsp;<\/li>\n<li>In the coming years, the&nbsp;Alzheimer&#8217;s disease (AD)&nbsp;market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;<\/li>\n<li>The companies and academics that are working to assess challenges and seek opportunities that could influence&nbsp;Alzheimer&#8217;s disease (AD)&nbsp;R&amp;D. The therapies under development are focused on novel approaches to treat\/improve the disease condition.<\/li>\n<li>A detailed portfolio of major pharma players who are involved in fueling the&nbsp;Alzheimer&#8217;s disease (AD)&nbsp;treatment market. Several potential therapies for&nbsp;Alzheimer&#8217;s disease (AD)&nbsp;are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the&nbsp;Alzheimer&#8217;s disease (AD)&nbsp;market size in the coming years.&nbsp;&nbsp;<\/li>\n<li>Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of&nbsp;Alzheimer&#8217;s disease (AD)) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request a Free Sample Report @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/alzheimers-disease-ad-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/alzheimers-disease-ad-pipeline-insight<\/a><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Key Questions<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What are the current options for&nbsp;Alzheimer&#8217;s disease (AD)&nbsp;treatment?<\/li>\n<li>How many companies are developing therapies for the treatment of&nbsp;Alzheimer&#8217;s disease (AD)?&nbsp;<\/li>\n<li>What are the principal therapies developed by these companies in the industry?<\/li>\n<li>How many therapies are developed by each company for the treatment of&nbsp;Alzheimer&#8217;s disease (AD)?<\/li>\n<li>How many&nbsp;Alzheimer&#8217;s disease (AD)&nbsp;emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of&nbsp;Alzheimer&#8217;s disease (AD)?<\/li>\n<li>Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?&nbsp;<\/li>\n<li>What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact&nbsp;Alzheimer&#8217;s disease (AD)&nbsp;market?&nbsp;<\/li>\n<li>Which are the dormant and discontinued products and the reasons for the same?<\/li>\n<li>What is the unmet need for current therapies for the treatment of&nbsp;Alzheimer&#8217;s disease (AD)?&nbsp;&nbsp;<\/li>\n<li>What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing&nbsp;Alzheimer&#8217;s disease (AD)&nbsp;therapies?&nbsp;<\/li>\n<li>What are the clinical studies going on for&nbsp;Alzheimer&#8217;s disease (AD)&nbsp;and their status?<\/li>\n<li>What are the results of the clinical studies and their safety and efficacy?&nbsp;<\/li>\n<li>What are the key designations that have been granted for the emerging therapies for&nbsp;Alzheimer&#8217;s disease (AD)?&nbsp;<\/li>\n<li>How many patents are granted and pending for the emerging therapies for the treatment of&nbsp;Alzheimer&#8217;s disease (AD)?&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports: <\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">Alzheimer&#8217;s disease (AD) &#8211; Market Insight, Epidemiology and Market Forecast -2030<\/a><\/p>\n<p style=\"text-align: justify;\">The Alzheimer&#8217;s disease (AD) market report provides current treatment practices, emerging drugs, Alzheimer&#8217;s disease (AD) market share of the individual therapies, current and forecasted Alzheimer&#8217;s disease (AD) market Size from 2017 to 2030 segmented by seven major markets.<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-epidemiology-forecast\">Alzheimer&rsquo;s disease &#8211; Epidemiology Forecast to 2030<\/a><\/p>\n<p style=\"text-align: justify;\">The Alzheimer&rsquo;s disease epidemiology covered in the report provides historical as well as forecasted Alzheimer&rsquo;s disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_55879.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=alzheimers-disease-clinical-trial-insight-pipeline-assessment-emerging-drugs-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=alzheimers-disease-clinical-trial-insight-pipeline-assessment-emerging-drugs-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alzheimer&#8217;s disease (AD) Pipeline Insight, 2020 DelveInsight has launched a new report on Alzheimer&#8217;s disease (AD) Pipeline Insight, 2020 &#8220;Alzheimer&#8217;s disease (AD) Pipeline Insight, 2020&#8221; report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/alzheimers-disease-clinical-trial-insight-pipeline-assessment-emerging-drugs-delveinsight_477020.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,423,403,404],"tags":[],"class_list":["post-477020","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Professional-Services","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=477020"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/477020\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=477020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=477020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=477020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}